These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34959657)

  • 1. Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists.
    Kawazoe M; Kihara M; Nanki T
    Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-level interest in anti-rheumatic drugs in the COVID-19 era: insights from Google Trends.
    Kardeş S; Kuzu AS; Pakhchanian H; Raiker R; Karagülle M
    Clin Rheumatol; 2021 May; 40(5):2047-2055. PubMed ID: 33130946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaco-Immunomodulatory Therapy in COVID-19.
    Rizk JG; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Forthal DN
    Drugs; 2020 Sep; 80(13):1267-1292. PubMed ID: 32696108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.
    Rabiu Abubakar A; Ahmad R; Rowaiye AB; Rahman S; Iskandar K; Dutta S; Oli AN; Dhingra S; Tor MA; Etando A; Kumar S; Irfan M; Gowere M; Chowdhury K; Akter F; Jahan D; Schellack N; Haque M
    Life (Basel); 2022 Mar; 12(4):. PubMed ID: 35454970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update.
    Prieto-Peña D; Dasgupta B
    Pol Arch Intern Med; 2021 Feb; 131(2):171-181. PubMed ID: 32550671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of monoclonal antibody drugs in the treatment of COVID-19.
    Ucciferri C; Vecchiet J; Falasca K
    World J Clin Cases; 2020 Oct; 8(19):4280-4285. PubMed ID: 33083387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S; Sun W; Li M; Dong L
    Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
    Zizzo G; Tamburello A; Castelnovo L; Laria A; Mumoli N; Faggioli PM; Stefani I; Mazzone A
    Front Immunol; 2022; 13():795315. PubMed ID: 35340805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.
    Mohammed MA
    Front Pharmacol; 2023; 14():1111329. PubMed ID: 37124230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis and treatment of cytokine storm in COVID-19.
    Soy M; Keser G; Atagündüz P
    Turk J Biol; 2021; 45(4):372-389. PubMed ID: 34803441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
    [No Abstract]   [Full Text] [Related]  

  • 13. Colchicine Against SARS-CoV-2 Infection: What is the Evidence?
    Drosos AA; Pelechas E; Drossou V; Voulgari PV
    Rheumatol Ther; 2022 Apr; 9(2):379-389. PubMed ID: 35107804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
    Cavalli G; Farina N; Campochiaro C; De Luca G; Della-Torre E; Tomelleri A; Dagna L
    Front Pharmacol; 2020; 11():598308. PubMed ID: 33442386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokine Storm and Immunomodulation in COVID-19.
    Rangappa P
    Indian J Crit Care Med; 2021 Nov; 25(11):1288-1291. PubMed ID: 34866828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology.
    Yokota S; Miyamae T; Kuroiwa Y; Nishioka K
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33671159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
    Pelechas E; Drossou V; Voulgari PV; Drosos AA
    Mediterr J Rheumatol; 2020 Sep; 31(Suppl 2):259-267. PubMed ID: 33196003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory mechanisms of abatacept: A therapeutic strategy for COVID-19.
    Yang D; Li H; Chen Y; Ren W; Dong M; Li C; Jiao Q
    Front Med (Lausanne); 2022; 9():951115. PubMed ID: 35957855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposal for a new nomenclature of disease-modifying antirheumatic drugs.
    Smolen JS; van der Heijde D; Machold KP; Aletaha D; Landewé R
    Ann Rheum Dis; 2014 Jan; 73(1):3-5. PubMed ID: 24072562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.